Skip to main content

Table 2 Clinical characteristics of the patients treated for PEDs with EGF ointment

From: Effect of epidermal growth factor ointment on persistent epithelial defects of the cornea

Patient No.

Primary diseases

Age, years

Sex

Visual acuity, LogMAR

VAS score

Esthesiometer score, mm

Area of epithelial defect, mm2

Time of healing, weeks

Outcomes

Baseline

2 month

Baseline

2 month

Baseline

2 month

Baseline

2 month

1

Dry eye disease

80 ~ 89

F

1.3

0.6

4

2

15

15

10

0

8

Healed

2

Herpetic keratitis

70 ~ 79

M

1.3

1.2

5

3

15

15

9

0

6

Healed

3

Herpetic keratitis

70 ~ 79

M

0.1

0.1

3

2

5

15

3

0

6

Healed

4

Dry eye disease

50 ~ 59

F

0.1

0.1

2

2

5

15

2

0

6

Healed

5

Herpetic keratitis

70 ~ 79

M

1.3

1.2

6

2

5

15

4

0

8

Healed

6

Dry eye disease

60 ~ 69

F

0.5

0.1

4

2

10

10

3

0

4

Healed

7

Herpetic keratitis

60 ~ 69

M

1.3

1.2

4

2

5

15

3

0

2

Healed

8

Limbal stem cell deficiency

80 ~ 89

F

1.3

1.2

6

3

5

10

2

0

6

Healed

9

Herpetic keratitis

70 ~ 79

F

1.0

1.0

4

5

10

5

4

5

AMT

10

Bacterial keratitis

50 ~ 59

M

1.3

1.2

4

3

10

10

10

0

8

Healed

11

Bacterial keratitis

70 ~ 79

M

0.4

0.1

5

3

10

10

4

0

2

Healed

12

Bacterial keratitis

70 ~ 79

F

1.3

0.1

5

2

5

5

4

1

Partially healed

13

Diabetic neurotrophic keratitis

60 ~ 69

M

1.7

1.3

6

6

5

5

9

7

AMT

14

Limbal stem cell deficiency

20 ~ 29

M

0.2

0.1

6

4

5

5

4

0

4

Healed

15

Filamentary keratitis

40 ~ 49

M

1.7

1.3

6

7

10

10

15

15

AMT

  1. PEDs Persistent epithelial defects of the cornea, EGF Epidermal growth factor, LogMAR Logarithm of the minimum angle of resolution, VAS Visual analogue scale, AMT Amniotic membrane transplantation